| __timestamp | Bausch Health Companies Inc. | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 9689000 |
| Thursday, January 1, 2015 | 2682700000 | 10431000 |
| Friday, January 1, 2016 | 2810000000 | 9618000 |
| Sunday, January 1, 2017 | 2582000000 | 12348000 |
| Monday, January 1, 2018 | 2473000000 | 28310241 |
| Tuesday, January 1, 2019 | 2554000000 | 59336147 |
| Wednesday, January 1, 2020 | 2367000000 | 159145941 |
| Friday, January 1, 2021 | 2624000000 | 199800000 |
| Saturday, January 1, 2022 | 2625000000 | 90225000 |
| Sunday, January 1, 2023 | 2917000000 | 92538000 |
Unleashing insights
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Bausch Health Companies Inc. and MorphoSys AG have demonstrated contrasting approaches. Bausch Health's SG&A expenses have consistently hovered around the $2.5 billion mark, peaking at $2.9 billion in 2023, reflecting a steady commitment to maintaining its market presence. In contrast, MorphoSys AG's SG&A spending has seen a dramatic increase, rising from a modest $9.7 million in 2014 to nearly $200 million in 2021, before stabilizing around $90 million in 2023. This 20-fold increase highlights MorphoSys AG's aggressive expansion strategy. As these companies navigate the competitive landscape, their SG&A spending patterns offer a window into their strategic priorities and market positioning.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Insmed Incorporated and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.